Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.

The Journal of pathology - 1 Jun 2024

Jin Kaifeng, Xu Jingtong, Su Xiaohe, Xu Ziyue, Li Bingyu, Liu Ge, Liu Hailong, Wang Yiwei, Zhu Yu, Xu Le, Zhang Weijuan, Liu Zhaopei, Wang Zewei, Chang Yuan, Xu Jiejie

Abstract excerpt

TP53 mutation is one of the most common genetic alterations in urothelial carcinoma (UrCa), and heterogeneity of TP53 mutants leads to heterogeneous clinical outcomes. This study aimed to investigate the clinical relevance of specific TP53 mutations in UrCa. In this study, a total of eight cohorts were enrolled, along with matched clinical annotation. TP53 mutations were classified as disruptive and nondisruptive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Transitional Cell

Share to Immune Checkpoint Inhibitors

Share to Programmed Cell Death 1 Receptor

Share to Tumor Microenvironment

Share to Tumor Suppressor Protein p53

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 38380548
DOI: 10.1002/path.6266

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.PMID 38380548Read ↗

TP53 mutations in urothelial carcinoma: not all one and the same†.Semantic proximity Read ↗

Mutational Landscape of TP53 Across Cancer TypesSemantic proximity Read ↗

Molecular classification and diagnostics of upper urinary tract urothelial carcinoma.Semantic proximity Read ↗

Prevalence, causes and impact of TP53-loss phenocopying events in human tumors.Semantic proximity Read ↗

Clinical Outcomes of TP53 Mutations in Cancers.Semantic proximity Read ↗

TP53 mutations as potential prognostic markers for specific cancers: Analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 DatabaseSemantic proximity Read ↗

TP53 mutations in epithelial ovarian cancerSemantic proximity Read ↗

Prevalence, causes and impact of <i>TP53</i> -loss phenocopying events in human tumorsSemantic proximity Read ↗

Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma.Semantic proximity Read ↗

TP53 missense–specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancerSemantic proximity Read ↗

Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

Mutant TP53 Hotspot Variants Differentially Rewire the Caspase Regulatory Network Across Cancer Lineages: A Pan-Cancer Computational Pharmacology AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.